Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients

被引：7
|
作者：
Leung, Abraham C. F.
Kummar, Shivaani
Agarwala, Sanjiv S.
Nemunaitis, John J.
Gonzalez, Rene
Drabick, Joseph J.
Schmidt, Emmett V.
Chartash, Elliot
Xing, Biao
Currie, Graeme
Janssen, Robert
Ribas, Antoni
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9550
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Ribas, Antoni
    Milhem, Mohammed M.
    Hoimes, Christopher J.
    Amin, Asim
    Mehmi, Inderjit
    Lao, Christopher D.
    Conry, Robert Martin
    Shaheen, Montaser F.
    Jang, Sekwon
    Salama, April K. S.
    Deva, Sanjeev
    Medina, Theresa Michelle
    Schmidt, Emmett V.
    Leung, Abraham C. F.
    Xing, Biao
    Janssen, Robert
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy.
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Amin, Asim
    Lao, Christopher D.
    Conry, Robert Martin
    Hunt, Jason
    Daniels, Gregory A.
    Almubarak, Mohammed
    Shaheen, Montaser F.
    Medina, Theresa Michelle
    Barve, Minal A.
    Bishnoi, Sarwan K.
    Abdi, Ehtesham A.
    Chisamore, Michael Jon
    Xing, Biao
    Candia, Albert
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
    Cohen, Ezra E. W.
    Nabell, Lisle
    Wong, Deborah J. L.
    Day, Terry A.
    Daniels, Gregory A.
    Milhem, Mohammed M.
    Deva, Sanjeev
    Jameson, Michael B.
    Guntinas-Lichius, Orlando
    Almubarak, Mohammed
    Strother, Robert Matthew
    Whitman, Eric D.
    Chisamore, Michael Jon
    Obiozor, Cynthia Chinedu
    Bagulho, Teresa
    Candia, Albert
    Gamelin, Erick
    Janssen, Robert
    Algazi, Alain Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
    Amin, Asim
    Milhem, Mohammed M.
    Long, Georgina V.
    Hoimes, Christopher J.
    Medina, Theresa Michelle
    Conry, Robert Martin
    Lao, Christopher D.
    Daniels, Gregory A.
    Reddy, Sunil A.
    Andtbacka, Robert Hans Ingemar
    Barve, Minal A.
    Shaheen, Montaser F.
    Tueting, Thomas
    Chisamore, Michael Jon
    Schmidt, Emmett V.
    Candia, Albert
    Obiozor, Cynthia Chinedu
    Gamelin, Erick
    Janssen, Robert
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Long, G. V.
    Milhem, M.
    Amin, A.
    Hoimes, C. J.
    Medina, T.
    Conry, R. M.
    Lao, C.
    Daniels, G.
    Reddy, S.
    Mehmi, I.
    Andtbacka, R. H. I.
    Barve, M.
    Shaheen, M.
    Tueting, T.
    Chisamore, M.
    Xing, B.
    Candia, A.
    Gamelin, E.
    Janssen, R.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, E. E. W.
    Algazi, A.
    Laux, D.
    Wong, D. J.
    Amin, A.
    Nabell, L.
    Chisamore, M.
    Gamelin, E.
    Janssen, R.
    Bishnoi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 375 - 375
  • [9] SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
    Ribas, Antoni
    Medina, Theresa
    Kummar, Shivaani
    Amin, Asim
    Kalbasi, Anusha
    Drabick, Joseph J.
    Barve, Minat
    Daniels, Gregory A.
    Wong, Deborah J.
    Schmidt, Emmett, V
    Candia, Albert F.
    Coffmanm, Robert L.
    Leung, Abraham C. F.
    Janssen, Robert S.
    CANCER DISCOVERY, 2018, 8 (10) : 1250 - 1257
  • [10] Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study
    Ribas, Antoni
    Medina, Theresa
    Kummar, Shivaani
    Amin, Asim
    Drabick, Joseph J.
    Barve, Minal
    Daniels, Gregory
    Wong, Deborah L.
    Schmidt, Emmett V.
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
12345